Related Experiment Videos
New drug developments for patients with metastatic soft tissue sarcoma
Jörg Thomas Hartmann1, Shreyaskumar Patel
1Department of Hematology/Oncology/Immunology/Rheumatology, UKT-Medical Center II, Eberhard-Karls-University Tuebingen, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany. joerg.hartmann@med.uni-tuebingen.de
Current Oncology Reports
|June 11, 2005
Summary
Targeted therapy imatinib mesylate offers progress for inoperable gastrointestinal stromal tumors. However, effective treatments for metastatic adult soft tissue sarcomas, particularly after standard chemotherapy failure, remain limited.
Area of Science:
- Oncology
- Medical Therapeutics
- Sarcoma Research
Background:
- Inoperable gastrointestinal stromal tumors (GIST) have seen progress with targeted therapy.
- Small round cell sarcomas (SRCT) are generally chemotherapy-sensitive and curable with neoadjuvant protocols.
- Metastatic adult soft tissue sarcomas (ASTS) have limited treatment options after failure of standard chemotherapy.
Purpose of the Study:
- To review the current landscape of treatment for specific sarcoma subtypes.
- To highlight advancements in targeted therapy for GIST.
- To address the unmet need for effective agents in metastatic ASTS.
Main Methods:
- Literature review of targeted therapies and chemotherapy for sarcomas.
- Analysis of treatment outcomes for GIST and ASTS.
- Discussion of therapeutic strategies for refractory metastatic ASTS.
Main Results:
- Imatinib mesylate represents significant progress for inoperable GIST.
- SRCTs demonstrate sensitivity to chemotherapy and potential curability.
- Limited effective cytotoxic agents exist for metastatic ASTS post-anthracycline and ifosfamide treatment.
Conclusions:
- Targeted therapy has transformed GIST treatment.
- While SRCTs are manageable, a significant challenge remains in treating advanced ASTS.
- Further research is needed to identify novel therapeutic agents for metastatic ASTS.